Is Bliss GVS Pharma overvalued or undervalued?

As of 18 November 2025, Bliss GVS Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 16.15, an EV to EBITDA of 13.09, and a PEG Ratio of 0.91, which suggest that the stock is reasonably priced relative to its earnings growth potential.
In comparison to its peers, Bliss GVS Pharma's valuation stands out against companies such as Sun Pharma, which is considered expensive with a PE Ratio of 36.56, and Cipla, which is rated attractive with a PE Ratio of 22.49. The recent stock performance of Bliss GVS Pharma has outpaced the Sensex, with a 1-year return of 38.54% compared to the Sensex's 9.48%, reinforcing its competitive position in the market.